Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Express Scripts Reports Specialty Drug Spending Steadily Rising, And Pipelines Show More To Come

Executive Summary

Not only are specialty drugs “the fastest-growing segment of drug spend,” but the pharmacy benefits manager Express Scripts predicts that specialty drug spend will account for 40% of U.S. drug expenditures by 2014.

You may also be interested in...



Express Scripts Planning Active Role In Insurance Exchanges

During the PBM’s fourth-quarter earnings call, CEO George Paz pointed out that Express Scripts is well positioned strategically for the exchange market because its insurance company clients will be participating in those states where the greatest numbers of enrollees are expected.

Despite Specialty Rx Growth, Overall Medicare Drug Spend Rose Only 1.3% Per Member Per Month – Express Scripts

While Medicare spending on expensive specialty drugs continues to outpace spending on traditional drugs, spending per member per month on Medicare drugs overall rose only 1.3% to $197.30 in 2010, according to pharmacy benefits manager Express Scripts.

Despite Specialty Rx Growth, Overall Medicare Drug Spend Rose Only 1.3% Per Member Per Month – Express Scripts

While Medicare spending on expensive specialty drugs continues to outpace spending on traditional drugs, spending per member per month on Medicare drugs overall rose only 1.3% to $197.30 in 2010, according to pharmacy benefits manager Express Scripts.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS053350

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel